Dendritic cell activating peptides induce distinct cytokine profiles.

Area of Science:

• Immunology
• Molecular Biology
• Cell Biology

Background:

• High-mobility group box 1 protein (HMGB1) is a pro-inflammatory cytokine involved in immune responses.
• HMGB1 and its B box domain are known to induce maturation of human dendritic cells (DCs).

Purpose of the Study:

• To investigate the effects of the HMGB1 B box domain and specific HMGB1-derived peptides on murine bone marrow-derived dendritic cells (BM-DCs).
• To evaluate the potential of these activated DCs as stimulators of T cell responses for immunotherapeutic applications.

Main Methods:

• Treatment of BM-DCs with HMGB1 B box domain or synthetic peptides.
• Analysis of DC phenotypic maturation markers (CD86, CD40, MHC-II) via flow cytometry.
• Measurement of cytokine and chemokine secretion (IL-1beta, IL-2, IL-5, IL-8, IL-12, TNF-alpha, IL-6, IL-10, IL-18) using ELISAs.
• Assessment of DC-mediated T cell activation in mixed leukocyte reactions and syngeneic T cell proliferation assays.

Main Results:

• The HMGB1 B box domain induced phenotypic maturation of BM-DCs, increasing CD86, CD40, and MHC-II expression.
• The B box domain enhanced secretion of pro-inflammatory cytokines (IL-1beta, IL-2, IL-5, IL-8, IL-12, TNF-alpha) but not IL-6 or IL-10.
• Four HMGB1-derived peptides induced IL-1beta, IL-2, and IL-12 production, with varying capacities to induce TNF-alpha, IL-5, IL-18, and IL-8.
• Activated DCs, by either the B box domain or peptides, potently stimulated allogeneic and syngeneic T cells, leading to proliferation.

Conclusions:

• The HMGB1 B box domain and specific peptides effectively mature DCs and enhance their immunostimulatory functions.
• These findings highlight the potential of HMGB1-derived peptides as adjuvants for immunotherapies and vaccines.
• The selective activity of different peptides offers a strategy for tailoring DC functional properties to specific immune contexts.